| FUS — Fused in Sarcoma | |
|---|---|
| Symbol | FUS |
| Full Name | Fused in Sarcoma |
| Chromosome | 16p11.2 |
| NCBI Gene | 2521 |
| Ensembl | ENSG00000089280 |
| OMIM | 137070 |
| UniProt | P35637 |
| Diseases | [ALS](/diseases/als), [Frontotemporal Dementia](/diseases/ftd) |
| Expression | Motor cortex, Spinal cord, Nucleus (widespread) |
| Key Mutations | |
| R521C, R521G, R521H, P525L, H517Q, G507D, R514G, R516G | |
Fus — Fused In Sarcoma is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
FUS (Fused in Sarcoma) is a gene located on chromosome 16p11.2 that encodes an RNA-binding protein involved in multiple aspects of RNA metabolism, including transcription, splicing, transport, and translation. FUS is highly expressed in neuronal tissues and plays critical roles in neuronal development, function, and survival. Mutations in FUS are causally linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), representing a key intersection between these two neurodegenerative disorders [1][2].
The FUS protein belongs to the FET (FUS, EWSR1, TAF15) family of RNA-binding proteins, which are characterized by their involvement in chromosomal translocations that generate oncogenic fusion proteins in various cancers. However, the focus of this page is on FUS's normal physiological functions and its pathogenic role in neurodegeneration.
The FUS protein (526 amino acids, ~59 kDa) contains several distinct structural domains that mediate its diverse functions:
N-terminal low-complexity (LC) domain: This glycine-rich region (amino acids 1-214) is enriched in tyrosine, glutamine, serine, and glycine residues. The LC domain is involved in protein-protein interactions and is critical for phase separation and liquid-liquid phase separation (LLPS) behavior [3][4].
RNA recognition motif (RRM): Located in the central region (amino acids 285-371), the RRM specifically binds RNA sequences and is essential for FUS's function in RNA processing [5].
Zinc finger (ZnF) domain: This CCHC-type zinc finger (amino acids 422-453) contributes to RNA binding specificity and protein interactions [6].
C-terminal prion-like domain: Similar to the N-terminal LC domain, this region (amino acids 456-526) contains prion-like sequences that can undergo aggregation in disease states [7].
FUS is a multifunctional RNA-binding protein involved in:
FUS plays a role in the cellular response to DNA damage:
During development, FUS is essential for:
Mutations in FUS account for approximately 5-10% of familial ALS cases and rare cases of sporadic ALS [13]. The majority of disease-causing mutations cluster in the C-terminal nuclear localization signal (NLS) region, which impairs FUS nuclear import. Pathological hallmarks include:
FUS pathology is also observed in certain subtypes of FTD, particularly in cases with motor neuron disease-like features:
Several mechanisms have been proposed to explain how FUS mutations lead to neurodegeneration:
Multiple animal models have been developed to study FUS-related neurodegeneration:
While FUS is primarily associated with ALS and FTD, emerging research suggests potential indirect connections to Alzheimer's disease (AD) and Parkinson's disease (PD) through shared pathological mechanisms:
Understanding these connections may lead to shared therapeutic strategies:
See also: Stress Granule Homeostasis, Mitochondrial Dysfunction in Neurodegeneration, RNA Metabolism in Neurodegeneration
The study of Fus — Fused In Sarcoma has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
| FUS Variant | Location | Pathogenesis | Onset |
|---|---|---|---|
| R521C | RRM | Aggregation | Adult |
| R522G | RRM | Nuclear import defect | Adult |
| P525L | NLS | Severe misfolding | Juvenile |
| G156E | RGG2 | Aggregation | Adult |
Recent advances in FUS-linked ALS research have revealed new mechanisms and therapeutic approaches:
| Mutation | Location | Protein Domain | Disease Association | Pathogenic Mechanism |
|---|---|---|---|---|
| R521C | Exon 15 | RRM | ALS, FTD | Reduced nuclear import |
| R521G | Exon 15 | RRM | ALS | Impaired RNA binding |
| R522G | Exon 15 | RRM | ALS | Nuclear localization defect |
| P525L | Exon 15 | RRM | Early-onset ALS | Severe nuclear import defect |
| R514G | Exon 14 | RGG2 | ALS, FTD | Altered phase separation |
| G156E | Exon 6 | N-terminal | ALS | Enhanced aggregation |
| Domain | Amino Acids | Function | Disease Relevance |
|---|---|---|---|
| N-terminal Low-complexity | 1-239 | Phase separation, stress granules | Mutations increase aggregation |
| RRM | 285-371 | RNA binding | Mutations reduce binding |
| RGG1 | 372-413 | RNA binding | Mutations affect splicing |
| RGG2 | 421-453 | RNA binding | Altered stress response |
| RGG3 | 460-501 | Protein interactions | FTD mutations affect interactions |
| Zinc Finger | 506-523 | DNA/RNA binding | Mutations disrupt binding |
| NLS | 526-526 | Nuclear localization | Mutations cause cytoplasmic accumulation |
Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications (2025). 2025. ↩︎
The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis (2025). 2025. ↩︎
Carboplatin restores neuronal toxicity in FUS-linked amyotrophic lateral sclerosis (2025). 2025. ↩︎
Lipid nanoparticles and transcranial focused ultrasound enhance ASO delivery to the murine brain for ALS therapy (2025). 2025. ↩︎
DNA damage response defects induced by TDP-43 and mutant FUS cytoplasmic inclusions (2025). 2025. ↩︎
Release of FUS into the extracellular space is regulated by its amino-terminal prion-like domain (2025). 2025. ↩︎